KORU Medical Systems Inc (KRMD)

A. Company Overview

KORU Medical Systems Inc. is a medical device company that specializes in the development, manufacture, and commercialization of innovative and patient-centered large volume subcutaneous infusion solutions. The company operates primarily within the subcutaneous drug delivery market and adheres to the regulatory oversight of the United States Food and Drug Administration (FDA) and international quality management standards.

KORU Medical's primary focus is on mechanical infusion products, notably the FREEDOM Infusion Systems, which comprise the FREEDOM60® Syringe Driver, the FreedomEdge® Syringe Driver, the HIgH-Flo Subcutaneous Safety Needle Sets™, and the Precision Flow Rate Tubing™. These devices are designed specifically for the delivery of subcutaneous medications, catering mainly to patients with chronic illnesses requiring self-administration of therapies.

B. Business Model and Revenue Streams

KORU Medical generates revenue from three primary sources: domestic core operations, international core operations, and novel therapies. The domestic core is concentrated in the United States and Canada, while international core operations extend to various global markets.

The company derives its product revenue primarily from syringe drivers, tubing, and needle sales associated with the FDA-cleared delivery of subcutaneous drugs, especially immunoglobulins used in treating Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The segment for novel therapies includes revenues from feasibility and clinical trials conducted by biopharmaceutical companies as well as non-recurring engineering services aimed at customizing the FREEDOM System for various drug delivery applications.

C. Mission Statement

KORU Medical's mission statement emphasizes a commitment to enhancing the quality of life for patients worldwide by providing innovative, effective, and user-friendly drug delivery systems that facilitate at-home or alternate site self-administration of therapies.

D. Strategy and Market Positioning

KORU Medical aims to solidify and expand its leading position within the subcutaneous immunoglobulin (SCIg) market for large volume infusion systems (volumes greater than 10ml) intended for self-administration. The company seeks to achieve this through several strategic initiatives, including:

1. Clinical and Product Innovation: Continuous improvement of existing products and the introduction of new innovations to enhance the functionality of the FREEDOM System.
2. Commercial Excellence: Establishing a commercial strategy that includes partnerships with pharmaceutical companies, expanding geographically, and leveraging existing channels to increase market share.
3. Expansion into Novel Therapies: Identifying and capturing opportunities in the delivery of novel subcutaneous drug therapies, particularly those currently in the clinical development pipeline.

The growth of the SCIg market is supported by factors such as the increasing prevalence of chronic diseases and a rising patient preference for subcutaneous treatment options over traditional intravenous therapies.

E. Product Portfolio

KORU Medical’s flagship product, the FREEDOM System, serves as a versatile platform for administering a range of therapies, particularly in home care settings. Key components of the FREEDOM System include:

• FREEDOM60 Syringe Driver: Compatible with standard 60ml and 50ml syringes, this device offers controlled subcutaneous medication delivery.
• FreedomEdge Syringe Driver: Designed for use with smaller syringes (30ml and 20ml), enhancing flexibility in treatment options.
• HIgH-Flo Subcutaneous Safety Needle Sets: Available in 26- and 24-gauge sizes, these needle sets feature safety mechanisms for effective self-administration.
• Precision Flow Rate Tubing: Regulates the flow of medication to ensure consistent delivery rates, minimizing drug waste.

The FREEDOM System is FDA-cleared for various indications, including the delivery of leading immunoglobulins and antibiotics through subcutaneous routes.

F. Sales and Distribution Channels

The FREEDOM System is distributed both directly and through medical device distributors, specifically targeting pharmaceutical companies, specialty pharmacies, and home infusion providers. A significant share of revenue comes from a concentrated network of distributors, with a small number of distributors collectively accounting for approximately 74% of net revenues.

Educational resources and training materials are provided to healthcare professionals and patients to ensure effective use of KORU Medical’s products and enhance market penetration.

G. Manufacturing and Supply Chain

KORU Medical manages its manufacturing operations within its facility in Mahwah, New Jersey, where it assembles and packages its pump products. Approximately 80% of consumables are manufactured by Command Medical Products, Inc., a contract manufacturing organization in Nicaragua.

The company relies heavily on single-source suppliers for key components, which streamlines compliance with regulatory approvals but also imposes risks related to supplier dependence.

H. Research and Development

Research and development (R&D) plays a pivotal role in KORU Medical's strategy, allocating significant resources to foster innovation. In recent years, the company has invested millions in R&D to enhance product performance and develop new infusion technologies, including ambitions for a next-generation infusion pump and consumable system.

I. Regulatory Compliance

KORU Medical's products are subject to stringent regulations mandated by the FDA and global health authorities. The company must navigate complex laws governing the development, testing, manufacturing, marketing, and distribution of its medical devices. The regulatory landscape requires ongoing compliance efforts, including regular inspections and quality assurance processes.

J. Competition and Market Dynamics

The infusion device market is highly competitive, with KORU Medical facing competition from various technologies, including electronic pumps and elastomeric pumps. Factors influencing device selection include safety, ease of use, cost, and effectiveness. In particular, the company positions the FREEDOM System as the leading delivery system in the U.S. for treatments requiring subcutaneous immunoglobulin administration.

K. Intellectual Property

KORU Medical holds an extensive portfolio of patents and other intellectual property rights to protect its innovations in drug delivery systems. As of the latest reporting, the company has 15 U.S. patents and 60 foreign patents, with patents extending beyond 2039 for its core technologies.

L. Leadership and Human Capital

As of December 2023, KORU Medical employs 82 individuals, contributing to its vision through diverse roles that involve product development, sales, and regulatory compliance. The leadership team comprises experienced executives with deep backgrounds in the medical device and healthcare industries, driving strategic initiatives and operational excellence.